Loading clinical trials...
Loading clinical trials...
Immunogenicity and Safety of SARS-CoV-2 Recombinant Protein Vaccines With AS03 Adjuvant in Adults 18 Years of Age and Older as a Primary Series and Immunogenicity and Safety of a Booster Dose of SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (Two Monovalent and One Bivalent)
Conditions
Interventions
SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 1
SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 2
+9 more
Locations
66
United States
Synexus - Clinical Research Advantage, Inc. Site Number : 8400270
Birmingham, Alabama, United States
Synexus Chandler Site Number : 8400251
Chandler, Arizona, United States
Synexus - Glendale. Site Number : 8400271
Glendale, Arizona, United States
Baptist Health Center for Clinical Research Site Number : 8400077
Little Rock, Arkansas, United States
Charles R. Drew University of Medicine and Science Site Number : 8400220
Los Angeles, California, United States
Peninsula Research Associates, Inc. Site Number : 8400094
Rolling Hills Estates, California, United States
Start Date
February 24, 2021
Primary Completion Date
June 29, 2023
Completion Date
June 29, 2023
Last Updated
September 18, 2025
NCT06631287
NCT05101213
NCT04565665
NCT06871293
NCT04978571
NCT07221162
Lead Sponsor
Sanofi Pasteur, a Sanofi Company
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions